APS1 and Immune Tolerance: From Basic Biology to Clinical Translation

APS1 is a multiorgan autoimmune disease caused by deleterious AIRE variants that impair central immune tolerance. This satellite symposium will address basic aspects of thymic epithelial cell biology, novel genetic mechanisms underlying APS1, high-throughput autoantibody screening and new autoantigen discovery, and novel pathogenetic mechanisms of T cell-driven tissue injury that have led to the development of effective personalized treatments in APS1 patients.

Organizing Societies
APS1 Foundation
Clinical Immunology Society (CIS)
NIAID

Session Chairs:
Mark Anderson, MD, PhD
University of California, San Francisco

Mihalis Lionakis, MD
National Institute of Allergy and Infectious Diseases

Session Agenda
1:30 PM - 1:50 PM
Landscape of TEC Development and Differentiation
Corey Miller, MD, PhD
Assistant Professor, UCSF

1:50 PM - 2:10 PM
TEC Differentiation
Matthieu Giraud, PhD
Senior Researcher, Nantes University

2:10 PM - 2:30 PM
Dynamics of Thymic Selection
Ellen Robey, PhD
Professor, University of California, Berkeley

2:30 PM - 2:50 PM
Human TEC Development
Audrey Parent, PhD
Assistant Professor, University of California, San Francisco

3:00 PM - 3:30 PM
Break

3:30 PM - 3:50 PM
High Throughput Screening of APS1 and Translation
Aaron Bodansky, MD,
UCSF Clinical Fellow, University of California, San Francisco

3:50 PM - 4:10 PM
B Cells as Professional APCs in Autoimmunity
Bill Robinson, MD, PhD
Professor, Stanford

4:10 PM - 4:30 PM
Genetics of AIRE-Deficiency
Sebastian Ochoa, MD
Assistant Professor, Baylor College of Medicine

4:30 PM - 4:50 PM
Clinical Trial for APS1
Mihalis Lionakis MD, ScD
Senior Investigator, NIAID